Article Information
History
- July 23, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Natacha Madelon1,
- Kim Lauper2,
- Gautier Breville3,
- Irène Sabater Royo1,
- Rachel Goldstein1,
- Diego O. Andrey4,
- Alba Grifoni5,
- Alessandro Sette5,6,
- Claire-Anne Siegrist1,7,#,
- Axel Finckh2,
- Patrice H. Lalive1,3,
- Arnaud M. Didierlaurent1,#& and
- Christiane S. Eberhardt1,7,8,#&
- 1Center for vaccinology, Department of Pathology and Immunology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 2Department of Medicine, Division of Rheumatology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 3Department of Neurosciences, Division of Neurology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 4Department of Diagnostics, Division of Laboratory Medicine; University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 5Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla, USA
- 6Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, USA
- 7Center for Vaccinology and Department for Paediatrics, Geneva University Hospitals, Emory University School of Medicine, Atlanta, USA
- 8Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA
- ↵&corresponding author Arnaud Didierlaurent (Arnaud.didierlaurent{at}unige.ch) and Christiane S. Eberhardt (Christiane.Eberhardt{at}unige.ch), Centre Médical Universitaire, rue Michel-Servet 1 1211 Genève 4 – Switzerland, +41 22 379 57 77
Posted July 23, 2021.
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines
